Trial Profile
Phase II trial of durvalumab plus tremelimumab in combination with chemotherapy as a first-line treatment in patients with pancreatic ductal adenocarcinoma
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2015
Price :
$35
*
At a glance
- Drugs Antineoplastics (Primary) ; Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 03 Aug 2015 New trial record